Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
- PMID: 22541435
- PMCID: PMC3472002
- DOI: 10.1016/j.cell.2012.01.058
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Abstract
Tumor maintenance relies on continued activity of driver oncogenes, although their rate-limiting role is highly context dependent. Oncogenic Kras mutation is the signature event in pancreatic ductal adenocarcinoma (PDAC), serving a critical role in tumor initiation. Here, an inducible Kras(G12D)-driven PDAC mouse model establishes that advanced PDAC remains strictly dependent on Kras(G12D) expression. Transcriptome and metabolomic analyses indicate that Kras(G12D) serves a vital role in controlling tumor metabolism through stimulation of glucose uptake and channeling of glucose intermediates into the hexosamine biosynthesis and pentose phosphate pathways (PPP). These studies also reveal that oncogenic Kras promotes ribose biogenesis. Unlike canonical models, we demonstrate that Kras(G12D) drives glycolysis intermediates into the nonoxidative PPP, thereby decoupling ribose biogenesis from NADP/NADPH-mediated redox control. Together, this work provides in vivo mechanistic insights into how oncogenic Kras promotes metabolic reprogramming in native tumors and illuminates potential metabolic targets that can be exploited for therapeutic benefit in PDAC.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f6.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3472002/bin/nihms404373f7.gif)
Comment in
-
Pancreatic cancer: Mouse models link metabolism and deubiquitination with Kras.Nat Rev Clin Oncol. 2012 May 15;9(7):368. doi: 10.1038/nrclinonc.2012.85. Nat Rev Clin Oncol. 2012. PMID: 22584999 No abstract available.
Similar articles
-
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.Cell. 2014 Jul 3;158(1):185-197. doi: 10.1016/j.cell.2014.06.003. Epub 2014 Jun 19. Cell. 2014. PMID: 24954535 Free PMC article.
-
Loss of heterozygosity for KrasG12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2020 Jun 11;526(4):880-888. doi: 10.1016/j.bbrc.2020.03.137. Epub 2020 Apr 9. Biochem Biophys Res Commun. 2020. PMID: 32279996
-
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13. Gastroenterology. 2015. PMID: 25683115
-
Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.Cell Death Dis. 2022 Sep 24;13(9):817. doi: 10.1038/s41419-022-05259-w. Cell Death Dis. 2022. PMID: 36151074 Free PMC article. Review.
-
Critical role of oncogenic KRAS in pancreatic cancer (Review).Mol Med Rep. 2016 Jun;13(6):4943-9. doi: 10.3892/mmr.2016.5196. Epub 2016 Apr 27. Mol Med Rep. 2016. PMID: 27121414 Review.
Cited by
-
Oncogenes and tumor suppressor genes: functions and roles in cancers.MedComm (2020). 2024 May 31;5(6):e582. doi: 10.1002/mco2.582. eCollection 2024 Jun. MedComm (2020). 2024. PMID: 38827026 Free PMC article. Review.
-
Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.World J Gastroenterol. 2024 May 21;30(19):2575-2602. doi: 10.3748/wjg.v30.i19.2575. World J Gastroenterol. 2024. PMID: 38817665 Free PMC article.
-
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.Front Oncol. 2024 May 10;14:1402128. doi: 10.3389/fonc.2024.1402128. eCollection 2024. Front Oncol. 2024. PMID: 38800401 Free PMC article. Review.
-
Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
-
MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon.Front Oncol. 2024 Apr 30;14:1387535. doi: 10.3389/fonc.2024.1387535. eCollection 2024. Front Oncol. 2024. PMID: 38746674 Free PMC article.
References
-
- Boros LG, Lee PW, Brandes JL, Cascante M, Muscarella P, Schirmer WJ, Melvin WS, Ellison EC. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med. Hypotheses. 1998;50:55–59. - PubMed
-
- Boros LG, Lerner MR, Morgan DL, Taylor SL, Smith BJ, Postier RG, Brackett DJ. [1,2-13C2]-D-glucose profiles of the serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats. Pancreas. 2005;31:337–343. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K08 EB012859/EB/NIBIB NIH HHS/United States
- P50 CA086355/CA/NCI NIH HHS/United States
- P01 CA117969/CA/NCI NIH HHS/United States
- P01 CA120964/CA/NCI NIH HHS/United States
- 5P30CA006516-46/CA/NCI NIH HHS/United States
- P50 CA86355/CA/NCI NIH HHS/United States
- P30 CA006516/CA/NCI NIH HHS/United States
- R01 GM056203/GM/NIGMS NIH HHS/United States
- 5P01CA120964-05/CA/NCI NIH HHS/United States
- U24 CA092782/CA/NCI NIH HHS/United States
- T32 CA009382/CA/NCI NIH HHS/United States
- R01 CA157490/CA/NCI NIH HHS/United States
- T32 CA009382-26/CA/NCI NIH HHS/United States
- P01 CA117969-07/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous